Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study

BMC Infectious Diseases

Research Article

Jens Bukh¹  Henrik B Krarup²  Poul Schlichting³  Mette Kjær⁴  Alex L Laursen⁵  Nanna Hansen⁶  Nina Weis⁷  Niels Obel⁸  Peer B Christensen⁹  Axel Møller^1,10 

[1] Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, 2650, Hvidovre, Denmark;Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, 2100, Copenhagen Ø, Denmark;Department of Gastroenterology and Biochemistry, Unit for Molecular Diagnostics, Aalborg University Hospital, 9100, Aalborg, Denmark;Department of Gastroenterology, Herlev University Hospital, 2730, Herlev, Denmark;Department of Hepatology, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen Ø, Denmark;Department of Infectious Diseases, Aarhus University Hospital, Skejby, 8000, Aarhus, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, 2650, Hvidovre, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, 2650, Hvidovre, Denmark;Faculty of Health Sciences, University of Copenhagen, Denmark, 2100, Copenhagen Ø, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen Ø, Denmark;Department of Infectious Diseases, Odense University Hospital, 5000, Odense, Denmark;Department of Internal Medicine, Kolding Hospital, 6000, Kolding, Denmark;

关键词: Sustained Virological Response;    Treatment Initiation;    Sustained Virological Response Rate;    Routine Clinical Setting;    High Sustained Virological Response Rate;   

DOI  :  10.1186/1471-2334-11-177

 received in 2010-12-11, accepted in 2011-06-21,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThe effect of peginterferon and ribavirin treatment on chronic hepatitis C virus (HCV) infection has been established in several controlled clinical studies. However, the effectiveness of treatment and predictors of treatment success in routine clinical practice remains to be established. Our aim was to estimate the effectiveness of peginterferon and ribavirin treatment in unselected HCV patients handled in routine clinical practice. The endpoint was sustained virological response (SVR), determined by the absence of HCV RNA 24 weeks after the end of treatment.MethodsWe determined the proportion of SVR in a nationwide, population-based cohort of 432 patients with chronic HCV infection who were starting treatment, and analyzed the impact of known covariates on SVR by using a logistic regression analysis.ResultsThe majority of treated patients had genotype 1 (133 patients) and genotype 2/3 (285 patients) infections, with 44% and 72%, respectively, obtaining SVR. Other than genotype, the predictors of SVR were age ≤ 45 years at the start of treatment, completion of unmodified treatment, the absence of cirrhosis and non-European origin.ConclusionsThe effectiveness of peginterferon and ribavirin treatment for chronic hepatitis C in a routine clinical practice is comparable to that observed in controlled clinical trials, with a higher SVR rate in genotype 2 and 3 patients compared to genotype 1 patients. Our data further indicate that age at start of treatment is a strong predictor of SVR irrespective of HCV genotype, with patients 45 years or younger having a higher SVR rate.

【 授权许可】

Unknown   
© Hansen et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.